{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T22:57:30Z","timestamp":1648508250882},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00393-013-1169-y","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T14:54:40Z","timestamp":1376405680000},"page":"846-850","source":"Crossref","is-referenced-by-count":0,"title":["Sind die Empfehlungen zum Tuberkulosescreening noch zeitgem\u00e4\u00df?"],"prefix":"10.1007","volume":"72","author":[{"given":"D.","family":"Ernst","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.E.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Meyer-Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,15]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00393-010-0677-2","volume":"69","author":"Meyer-Olson","year":"2010","unstructured":"Meyer-Olson D, Hoeper K, Schmidt RE (2010) Infectious complications of biologic therapy in patients with rheumatoid arthritis. Z Rheumatol 69(10):879\u2013888","journal-title":"Z Rheumatol"},{"key":"1169_CR2","unstructured":"WHO (2012) Global tuberculosis report 2012. http:\/\/apps.who.int\/tb"},{"key":"1169_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1055\/s-0030-1255127","volume":"135","author":"Ernst","year":"2010","unstructured":"Ernst D, Bange FC, Rana A et al (2010) Reactivation of tuberculosis with Mycobacterium bovis infection of the oral mucosa during immunosuppression. Dtsch Med Wochenschr 135(23):1179\u20131181","journal-title":"Dtsch Med Wochenschr"},{"key":"1169_CR4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","volume":"72","author":"Winthrop","year":"2013","unstructured":"Winthrop K, Baxter R, Liu L et al (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37\u201342","journal-title":"Ann Rheum Dis"},{"key":"1169_CR5","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P et al (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884\u20131894","journal-title":"Arthritis Rheum"},{"key":"1169_CR6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1469-0691.2007.01891.x","volume":"14","author":"Denis","year":"2008","unstructured":"Denis B, Lefort A, Flipo RM et al (2008) Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. Clin Microbiol Infect 14(2):183\u2013186","journal-title":"Clin Microbiol Infect"},{"key":"1169_CR7","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"Carmona","year":"2005","unstructured":"Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766\u20131772","journal-title":"Arthritis Rheum"},{"key":"1169_CR8","doi-asserted-by":"crossref","first-page":"e1001012","DOI":"10.1371\/journal.pmed.1001012","volume":"8","author":"Zwerling","year":"2011","unstructured":"Zwerling A, Behr MA, Verma A et al (2011) The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 8(3):e1001012","journal-title":"PLoS Med"},{"key":"1169_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","volume":"37","author":"Diel","year":"2011","unstructured":"Diel R, Goletti D, Ferrara G et al (2011) Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37(1):88\u201399","journal-title":"Eur Respir J"},{"key":"1169_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177\u2013184","journal-title":"Ann Intern Med"},{"key":"1169_CR11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.21788","volume":"65","author":"Hsia","year":"2013","unstructured":"Hsia EC, Cush JJ, Matteson EL et al (2013) A comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials. Arthritis Care Res 65(2):309\u2013313","journal-title":"Arthritis Care Res"},{"key":"1169_CR12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00393-009-0475-x","volume":"68","author":"Diel","year":"2009","unstructured":"Diel R, Hauer B, Loddenkemper R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 68(5):411\u2013416","journal-title":"Z Rheumatol"},{"key":"1169_CR13","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","volume":"17","author":"Belard","year":"2011","unstructured":"Belard E, Semb S, Ruhwald M et al (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17(11):2340\u20132349","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR14","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/ar1994","volume":"8","author":"Hamdi","year":"2006","unstructured":"Hamdi H, Mariette X, Godot V et al (2006) Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 8(4):R114","journal-title":"Arthritis Res Ther"},{"key":"1169_CR15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","volume":"67","author":"Matulis","year":"2008","unstructured":"Matulis G, Juni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67(1):84\u201390","journal-title":"Ann Rheum Dis"},{"key":"1169_CR16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/ibd.21602","volume":"17","author":"Del","year":"2011","unstructured":"Del Tedesco E, Roblin X, Laharie D, Peyrin Biroulet L (2011) Does anti-TNF therapy influence the performance of Mycobacterium tuberculosis antigen-specific interferon-gamma assays? A French multicenter experience. Inflamm Bowel Dis 17(8):1824","journal-title":"Inflamm Bowel Dis"},{"key":"1169_CR17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","volume":"71","author":"Kleinert","year":"2012","unstructured":"Kleinert S, Tony HP, Krueger K et al (2012) Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-gamma release assays under real-life conditions. Ann Rheum Dis 71(11):1791\u20131795","journal-title":"Ann Rheum Dis"},{"key":"1169_CR18","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/annrheumdis-2011-200408","volume":"71","author":"Mariette","year":"2012","unstructured":"Mariette X, Baron G, Tubach F et al (2012) Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 71(11):1783\u20131790","journal-title":"Ann Rheum Dis"},{"key":"1169_CR19","first-page":"776","volume":"35","author":"Ponce","year":"2008","unstructured":"Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S et al (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776\u2013781","journal-title":"J Rheumatol"},{"key":"1169_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.medmal.2011.08.002","volume":"42","author":"Mrozek","year":"2012","unstructured":"Mrozek N, Pereira B, Soubrier M et al (2012) Screening of tuberculosis before biologics. Med Mal Infect 42(1):1\u20134","journal-title":"Med Mal Infect"},{"key":"1169_CR21","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","volume":"64","author":"Hsia","year":"2012","unstructured":"Hsia EC, Schluger N, Cush JJ et al (2012) Interferon-gamma release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 64(7):2068\u20132077","journal-title":"Arthritis Rheum"},{"key":"1169_CR22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"Gomez-Reino","year":"2007","unstructured":"Gomez-Reino JJ, Carmona L, Angel Descalzo M (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57(5):756\u2013761","journal-title":"Arthritis Rheum"},{"key":"1169_CR23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/annrheumdis-2012-201979","volume":"71","author":"Winthrop","year":"2012","unstructured":"Winthrop KL, Weinblatt ME, Daley CL (2012) You can\u2019t always get what you want, but if you try sometimes (with two tests \u2013 TST and IGRA \u2013 for tuberculosis) you get what you need. Ann Rheum Dis 71(11):1757\u20131760","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1169-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-013-1169-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-013-1169-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:15Z","timestamp":1559061375000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-013-1169-y"}},"subtitle":["Interferon-\u03b3-Release-Assay-Test und\/oder Tuberkulinhauttest zur Diagnostik einer latenten Tuberkuloseinfektion"],"short-title":[],"issued":{"date-parts":[[2013,8,15]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s00393-013-1169-y","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,15]]}}}